| Literature DB >> 33918543 |
Zuhura I Kimera1,2,3, Fauster X Mgaya1, Gerald Misinzo3,4, Stephen E Mshana5, Nyambura Moremi6, Mecky I N Matee1,3.
Abstract
We determined the phenotypic profile of multidrug-resistant (MDR) Escherichia coli isolated from 698 samples (390 and 308 from poultry and domestic pigs, respectively). In total, 562 Enterobacteria were isolated. About 80.5% of the isolates were E. coli. Occurrence of E. coli was significantly higher among domestic pigs (73.1%) than in poultry (60.5%) (p = 0.000). In both poultry and domestic pigs, E. coli isolates were highly resistant to tetracycline (63.5%), nalidixic acid (53.7%), ampicillin (52.3%), and trimethoprim/sulfamethoxazole (50.9%). About 51.6%, 65.3%, and 53.7% of E. coli were MDR, extended-spectrum beta lactamase-producing enterobacteriaceae (ESBL-PE), and quinolone-resistant, respectively. A total of 68% of the extended-spectrum beta lactamase (ESBL) producers were also resistant to quinolones. For all tested antibiotics, resistance was significantly higher in ESBL-producing and quinolone-resistant isolates than the non-ESBL producers and non-quinolone-resistant E. coli. Eight isolates were resistant to eight classes of antimicrobials. We compared phenotypic with genotypic results of 20 MDR E. coli isolates, ESBL producers, and quinolone-resistant strains and found 80% harbored blaCTX-M, 15% aac(6)-lb-cr, 10% qnrB, and 5% qepA. None harbored TEM, SHV, qnrA, qnrS, qnrC, or qnrD. The observed pattern and level of resistance render this portfolio of antibiotics ineffective for their intended use.Entities:
Keywords: Enterobacteriaceae; Msimbazi basin; antibiotics; antimicrobial resistance; domestic pigs; farmers; poultry
Year: 2021 PMID: 33918543 PMCID: PMC8069735 DOI: 10.3390/antibiotics10040406
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Frequency of Enterobacteriaceae isolates from poultry and domestic pigs.
| Organism | Isolates Recovered from Poultry ( | Isolates Recovered from Domestic Pigs ( | ||
|---|---|---|---|---|
| Number | Percentage | Number | Percentage | |
|
| 236 | 60.5 | 225 | 73.1 |
|
| 9 | 2.3 | 6 | 1.9 |
|
| 5 | 1.3 | 2 | 0.6 |
| 32 | 8.2 | 2 | 0.6 | |
|
| 5 | 1.3 | 1 | 0.3 |
| 5 | 1.3 | 1 | 0.3 | |
| 4 | 1.0 | 4 | 1.3 | |
| 8 | 2.1 | - | - | |
|
| 3 | 0.8 | 5 | 1.6 |
|
| 2 | 0.5 | 1 | 0.3 |
Figure 1Percentage of antibiotic resistance from the poultry and domestic pig isolates. Key: CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; GEN, gentamycin; AMP, ampicillin; TET, tetracycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; MEM, meropenem.
Comparative analysis of antibiotic resistance of isolates from poultry versus domestic pigs.
| Antibiotic | % of Resistance in Poultry ( | % of Resistance in Domestic Pigs ( | Chi-Square | |
|---|---|---|---|---|
| CIP ( | 28.5 | 28.6 | 0.360 | 0.835 |
| CHL ( | 27.2 | 27.3 | 0.360 | 0.835 |
| NAL ( | 47.3 | 38.0 | 10.090 | 0.006 |
| GEN ( | 27.7 | 26.0 | 0.845 | 0.655 |
| AMP ( | 39.0 | 46.4 | 3.997 | 0.136 |
| TET ( | 51.3 | 51.3 | 0.447 | 0.800 |
| DOX ( | 38.5 | 39.0 | 0.346 | 0.841 |
| SXT ( | 35.9 | 47.7 | 10.566 | 0.005 |
| CTX ( | 36.4 | 29.5 | 8.265 | 0.016 |
| MEM ( | 3.3 | 3.6 | 0.168 | 0.919 |
Key: CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; GEN, gentamycin; AMP, ampicillin; TET, tetracycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; MEM, meropenem.
Prevalence of antibiotic-resistant E. coli from poultry by ward.
| No. of | % of Resistance to the Tested Antibiotic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CIP | CHL | NAL | GEN | AMP | TET | DOX | SXT | CTX | MEM | |
| Ukonga (30) | 56.7 | 43.3 | 73.3 | 22.4 | 70.0 | 61.2 | 59.7 | 49.3 | 63.3 | 3.0 |
| Kipawa (67) | 32.8 | 29.9 | 64.2 | 30.0 | 52.2 | 80.0 | 66.7 | 56.7 | 43.3 | 10.0 |
| Gongolamboto (22) | 50.0 | 36.4 | 72.7 | 31.8 | 36.4 | 81.8 | 63.6 | 54.5 | 68.2 | 0.0 |
| Buguruni (15) | 33.3 | 20.0 | 46.7 | 40.0 | 40 | 60.0 | 20.0 | 26.7 | 33.3 | 6.7 |
| Kinyerezi (53) | 39.6 | 39.6 | 56.6 | 50.9 | 50.9 | 64.2 | 43.4 | 41.5 | 39.6 | 5.7 |
| Segerea (47) | 34.0 | 31.9 | 63.8 | 34.0 | 53.2 | 72.3 | 46.8 | 55.3 | 61.7 | 4.3 |
| Overall resistance | 39.3 | 34.2 | 63.2 | 34.2 | 52.1 | 68.4 | 52.1 | 48.7 | 50.4 | 4.7 |
| 0.237 | 0.569 | 0.419 | 0.046 | 0.223 | 0.254 | 0.018 | 0.315 | 0.026 | 0.599 | |
Key: CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; GEN, gentamycin; AMP, ampicillin; TET, tetracycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; MEM, meropenem.
Prevalence of antibiotic-resistant E. coli from domestic pigs by ward.
| No. of | % of Resistance to the Tested Antibiotic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CIP | CHL | NAL | GEN | AMP | TET | DOX | SXT | CTX | MEM | |
| Ukonga (42) | 23.8 | 21.4 | 33.3 | 19.0 | 27.8 | 50.0 | 27.8 | 33.3 | 42.9 | 5.6 |
| Kipawa (18) | 11.1 | 5.6 | 33.3 | 11.1 | 54.8 | 64.3 | 54.2 | 61.9 | 55.6 | 7.1 |
| Kinyerezi (35) | 34.3 | 25.7 | 37.1 | 25.7 | 54.3 | 51.4 | 37.1 | 62.9 | 20.0 | 0.0 |
| Segerea (58) | 24.1 | 22.4 | 43.1 | 22.4 | 48.3 | 53.4 | 41.4 | 41.4 | 27.6 | 1.7 |
| Kisarawe (51) | 60.8 | 62.7 | 64.7 | 47.1 | 76.5 | 80.4 | 60.8 | 80.4 | 47.1 | 11.8 |
| Pugu station (18) | 38.9 | 38.9 | 44.4 | 44.4 | 72.2 | 66.7 | 50.0 | 50.0 | 38.9 | 0.0 |
| Overall resistance | 34.2 | 32.0 | 44.6 | 28.8 | 57.2 | 62.2 | 46.8 | 57.7 | 36.7 | 5.0 |
| 0.000 | 0.000 | 0.031 | 0.006 | 0.003 | 0.033 | 0.101 | 0.000 | 0.034 | 0.022 | |
Key: CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; GEN, gentamycin; AMP, ampicillin; TET, tetracycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; MEM, meropenem.
Multidrug resistance patterns among 431 E. coli isolated from poultry and domestic pigs.
| No. of Antibiotics Classes | Resistance Pattern | No. of Isolates | Prevalence (%) |
|---|---|---|---|
| 3 | TET/SUL/CEP | 4 | 0.87 |
| QNL/PEN/SUL | 6 | 1.30 | |
| AMN/PEN/TET | 3 | 0.65 | |
| QNL/AMN/TET | 8 | 1.73 | |
| QNL/PEN/TET | 3 | 0.65 | |
| PEN/SUL/CEP | 2 | 0.43 | |
| QNL/PEN/TET | 5 | 1.08 | |
| PEN/TET/SUL | 14 | 3.04 | |
| QNL/TET/SUL | 6 | 1.30 | |
| PHE/TET/SUL | 3 | 0.65 | |
| QNL/TET/CEP | 3 | 0.65 | |
| 4 | QNL/AMN/TET/CEP | 5 | 1.08 |
| QNL/PEN/SUL/CEP | 4 | 0.87 | |
| QNL/AMN/TET/SUL | 3 | 0.65 | |
| QNL/PEN/TET/SUL | 15 | 3.25 | |
| PHE/QNL/PEN/TET | 3 | 0.65 | |
| PHE/PEN/TET/SUL | 4 | 0.87 | |
| PEN/TET/SUL/CEP | 2 | 0.43 | |
| QNL/TET/SUL/CEP | 4 | 0.87 | |
| 5 | QNL/AMN/TET/SUL/CEP | 3 | 0.65 |
| QNL/PEN/TET/SUL/CEP | 5 | 1.08 | |
| QNL/AMN/PEN/TET/SUL | 4 | 0.87 | |
| QNL/PHE/TET/SUL/CEP | 3 | 0.65 | |
| QNL/PHE/PEN/TET/SUL | 16 | 3.47 | |
| 6 | QNL/AMN/PEN/TET/SUL/CEP | 2 | 0.43 |
| QNL/PHE/AMN/PEN/TET/CEP | 2 | 0.43 | |
| QNL/PHE/PEN/TET/SUL/CEP | 3 | 0.65 | |
| QNL/PHE/AMN/PEN/TET/SUL | 20 | 4.34 | |
| 7 | QNL/PHE/PEN/TET/SUL/CEP/CAR | 11 | 2.39 |
| QNL/PHE/AMN/PEN/TET/SUL/CEP | 62 | 13.45 | |
| 8 | QNL/PHE/AMN/PEN/TET/SUL/CEP/CAR | 10 | 2.17 |
| Total | 238 | 51.6 | |
Key: QNL, quinolones; PHE, phenocols; AMN, aminoglycosides; PEN, penicillins; TET, tetracyclines; SUL, sulfonamides; CEP, cephalosporins; CAR, carbapenems.
Comparative antibiotic resistance of extended-spectrum beta lactamase (ESBL)- and non-ESBL-producing E. coli in cloacal and rectal swabs of poultry and domestic pigs.
| Antibiotic | % of Resistant ESBL | % of Resistant Non-ESBL | |
|---|---|---|---|
| Ciprofloxacin | 41.2(124) | 30.6(49) | 0.000 |
| Chloramphenicol | 36.2(109) | 28.1(45) | 0.000 |
| Nalidixic acid | 59.8(180) | 45.0(72) | 0.000 |
| Gentamycin | 33.6(101) | 29.4(47) | 0.000 |
| Tetracycline | 70.1(211) | 57.5(92) | 0.000 |
| Doxycycline | 52.5(158) | 45.6(73) | 0.000 |
| Trimethoprim/ | 55.5(167) | 50.0(80) | 0.000 |
Comparative antibiotic resistance of quinolone-resistant versus non-quinolone-resistant E. coli.
| Antibiotic | % Quinolone Resistance ( | % Non-Quinolone Resistance ( | Chi-Square | |
|---|---|---|---|---|
| Chloramphenicol | 70.5(122) | 11.1(32) | 171.469 | 0.000 |
| Gentamycin | 60.1(104) | 15.3(44) | 99.683 | 0.000 |
| Ampicillin | 82.1(142) | 37.2(107) | 87.830 | 0.000 |
| Tetracycline | 92.5(160) | 49.7(143) | 88.022 | 0.000 |
| Doxycycline | 80.9(140) | 31.6(91) | 105.191 | 0.000 |
| Trimethoprim/ | 82.7(143) | 36.1(104) | 94.152 | 0.000 |
| Cefotaxime | 52.0(90) | 40.6(117) | 5.675 | 0.017 |
| Meropenem | 11.0(19) | 1.0(3) | 24.028 | 0.000 |
Comparative results of ESBL producers against quinolone-resistant E. coli isolates.
| ESBL Producer Isolate | Quinolone-Resistant Isolate | ||||||
|---|---|---|---|---|---|---|---|
| R | S | R | S | ||||
| CHL | 36.2(109) | 63.8(192) | 0.080 | CHL | 70.5(122) | 11.1(32) | 0.000 |
| GEN | 33.6(101) | 64.4(200) | 0.360 | GEN | 60.1(104) | 15.3(44) | 0.000 |
| TET | 70.1(211) | 29.9(90) | 0.007 | TET | 92.5(160) | 49.7(143) | 0.000 |
| DOX | 52.5(158) | 47.5(143) | 0.160 | DOX | 80.9(140) | 31.6(91) | 0.000 |
| SXT | 55.5(167) | 44.5(134) | 0.261 | SXT | 82.7(143) | 36.1(104) | 0.000 |
Key: CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; GEN, gentamycin; AMP, ampicillin; TET, tetracycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; MEM, meropenem.
Distribution of ESBL and quinolone-resistant genes from the selected multidrug-resistant (MDR) E. coli (n = 20).
| AMR Genes | Sample Type | ||
|---|---|---|---|
| Poultry | Domestic Pigs | ||
|
| 16/20 (80) | 7 | 9 |
|
| 0/20 (0) | 0 | 0 |
|
| 0/20 (0) | 0 | 0 |
|
| 0/20 (0) | 0 | 0 |
|
| 2/20 (10) | 0 | 2 |
|
| 0/20 (0) | 0 | 0 |
|
| 0/20 (0) | 0 | 0 |
|
| 0/20 (0) | 0 | 0 |
| 3/20 (15) | 2 | 1 | |
|
| 1/20 (5) | 1 | 0 |
Figure 2Gel electrophoretic bands of ESBL and quinolone-resistant genotypes (qnrB, CTX-M, qepA, and aac(6)-lb-cr). Letters: M—DNA ladder, N—negative control, and P—positive control. Positive samples are numbers 1, 10, 12, 13, and 16 (qnrB, aac(6)-lb-cr, and qepA) and samples 1, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 20 (CTX-M).
PCR primers, sequences, and protocols used.
| Gene | Primer Set and Sequence (5′-3′) | Amplicon Size | Reference |
|---|---|---|---|
| CTX-M | F: SCSATGTGCAGYACCAGTAA | 585 bp | [ |
|
| F: TCAGCAAGAGGATTTCTCA | 627 bp | [ |
|
| F: GGMATHGAAATTCGCCACTG | 264 bp | [ |
|
| F: ATGGAAACCTACAATCATAC | 467 bp | [ |
| F: TTGCGATGCTCTATGAGTGGCTA | 482 bp | [ | |
| TEM | F: ATGAGTATTCAACATTTCCG | 868 bp | [ |
| SHV | F: GGTTATGCGTTATATTCGCC | 867 bp | [ |
|
| F: GGGTTGTACATTTATTGAATC | 447 bp | [ |
|
| F: CGAGATCAATTTACGGGGAATA | 582 bp | [ |
|
| F: TGGTCTACGCCATGGACCTCA | 1137 bp | [ |